0798-0000-19-111-H01-P (for Pharmacists) February (2.0 Contact hours)

The first biosimilar, Zarxio, was approved by the Food and Drug Administration (FDA) in 2015. Since then, 18 other biosimilars have been approved in the U.S. however less than half of them are commercially available on the market. The average whole sale prices of these biosimilars are approximately 15% to 60% lower than that of their respective reference products. In spite of the potential cost savings to health plans and patients, the adoption of biosimilars in the U.S. has been slow. It is important for healthcare providers to understand the current landscape of biosimilars, the agents that are available, their indications, and place in therapy.